Results 111 to 120 of about 5,337 (191)

Análise da eficácia clínica do fármaco Aducanumab no tratamento da Doença de Alzheimer [PDF]

A Doença de Alzheimer trata-se de um distúrbio neurodegenerativo progressivo, caracterizado pelo acúmulo da proteína β -amiloide no tecido parenquimatoso cerebral, levando a formação de placas amiloides na matriz extracelular entre os neurônios e ...
Turke, Camille Corcione, Estrela, Heder Frank Gianotto, Zumbano, Giulia Matiusso, Camargo, Rafaella Mendes, Chvojka Neto, Vladimir, Morelli, Sofia de Almeida, Akamine, Marcela Yumi Eleuterio, Shimada, Tatiana   +7 more
core   +1 more source

Sustaining Drug Discovery Amid the Limits of Alzheimer's Disease Immunotherapies. [PDF]

eNeuro
McDiarmid A.
europepmc   +1 more source

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease. [PDF]

Acta Neuropathol
Welikovitch LA, Oakley DH, Bennett RE, Serrano-Pozo A, Zhu H, Ruiz-Uribe NE, Zwang TJ, Chibnik LB, Gomez-Isla T, Frosch MP, Marks DS, Salloway S, Bernick C, Greeley D, Latimer CS, Nolan A, Hutchison RM, Rubel CE, Bussiere T, Plowey ED, Keene CD, Hyman BT.   +21 more
europepmc   +1 more source

Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. [PDF]

JAMA
Brown CA, Robinson JL, Das SR, McGrew E, Suh E, Van Deerlin VM, Irwin DJ, Nasrallah IM, Mechanic-Hamilton D, Yushkevich PA, Wolk DA, Lee EB.   +11 more
europepmc   +1 more source

Anti-amyloid nanobody-Fc fusion protein drives potent amyloid clearance through microglial recruitment. [PDF]

Alzheimers Dement (N Y)
Ding Z, Gibson KA, Nascari DG, Tallant LE, Bouchal SM, Dickson DW, Fryer JD.   +6 more
europepmc   +1 more source

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brain. [PDF]

Alzheimers Dement
Bjørnholm KD, Butler PM, Francis AE, Varma C, Spooner ET, Grenon MB, Xu YR, Tao Y, Meunier AL, Anderson AK, Hennessey EL, Miller MB, Selkoe DJ, Lemere CA, Stern AM.   +14 more
europepmc   +1 more source

A Narrative Review of Amyloid-β Monoclonal Antibodies for Alzheimer Disease: How Amyloid Species Engagement May Affect Clinical Outcomes. [PDF]

Neurologist
Caselli RJ, Geldmacher DS, Schilling TB.
europepmc   +1 more source

A reproducible three-dimensional model of human brain tissue to investigate physiological and disease-associated microglia phenotypes. [PDF]

Nat Neurosci
Klimmt J, Cardoso Gonçalves C, Montgomery JV, Müller SA, Bublitz M, Filser S, Paeger L, Nuscher B, Dannert A, Roeber S, Pravata V, Schifferer M, Shrouder JJ, Schulz N, González-Gallego J, Cappello S, Misgeld T, Plesnila N, Beltrán E, Herms J, De Domenico E, Beyer MD, Schultze JL, Haass C, Lichtenthaler SF, Carraro C, Paquet D.   +26 more
europepmc   +1 more source

Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community. [PDF]

Neurol Sci
Santos DH, da Silva AMP.
europepmc   +1 more source

Antiamyloid Antibody Effects on Aβ-42 Protein Aggregates Profiled Using Nanospectroscopy. [PDF]

Chem Biomed Imaging
Kummer N, Cihova M, Nirmalraj PN.
europepmc   +1 more source